Literature DB >> 3971652

Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.

C R Lehmann, J D Heironimus, C B Collins, T J O'Neil, W P Pierson, J T Crowe, A P Melikian, G J Wright.   

Abstract

Metoclopramide kinetics were examined in 24 adult patients with diminished renal function and in eight healthy subjects with normal renal function. Creatinine clearance correlated with metoclopramide plasma clearance, renal clearance, nonrenal clearance, and elimination t1/2. Regardless of renal function, renal clearance accounted for less than or equal to 21% of total plasma clearance. Nonrenal clearance was reduced in patients and accounted for most of the reduction in plasma clearance. The comparatively small plasma clearances in patients imply that maintenance doses should be reduced accordingly to avoid drug cumulation. Metoclopramide clearance by hemodialysis was also assessed in four patients. Metoclopramide losses from hemodialysis were relatively small compared to estimates of total body metoclopramide stores. Compensatory dosage increases are probably unnecessary for most patients. These data also suggest that hemodialysis is not likely to be effective in metoclopramide overdose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971652     DOI: 10.1038/clpt.1985.41

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Pharmacokinetics of metoclopramide in patients with liver cirrhosis.

Authors:  E Magueur; H Hagege; P Attali; E Singlas; J P Etienne; A M Taburet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis.

Authors:  F Albani; M R Tamè; R De Palma; M Bernardi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

4.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 5.  Metoclopramide in a patient with renal failure may be an increased risk of neuroleptic malignant syndrome.

Authors:  Y Fujita; T Yasukawa; M Mihira; T Sasaki; S Yokoya
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

Review 6.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 7.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

8.  Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.

Authors:  J Grevel; B Whiting; A W Kelman; W B Taylor; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 9.  Pharmacokinetics of high-dose metoclopramide in cancer patients.

Authors:  E M McGovern; J Grevel; S M Bryson
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.